A Case Illustrative of Phenotypic Heterogeneity and Challenges in the Management of Paraganglioma Abstract #22

Introduction: Paragangliomas (PGLs) are extra-adrenal, usually benign, highly vascularized tumors that originate from neural-crest-derived chromaffin cells. These tumors are subdivided as either sympathetic or parasympathetic, depending on their location and catecholamine production. Sympathetic PGLs are situated along the abdominal sympathetic trunk and usually produce catecholamines, whereas parasympathetic PGLs are located in the head and neck, and these usually do not produce catecholamines. PGLs may present as sporadic or inherited tumor syndrome, including MEN 2, with RET germline mutations, von Hippel-Lindau (VHL) disease due to germline mutations in VHL gene, and pheochromocytoma-PGL syndrome. The latter is frequently a hereditary condition and is caused by germline mutations in the SDHB, SDHC, or SDHC genes. Patients with familial PGLs may present at a younger age, often as multifocal tumors, with an increased risk of recurrence and a higher frequency of malignancy in those with SDHB mutations. SDH mutations induce angiogenesis and tumorogenesis through the inhibition of hypoxia-inducible factors (HIF)-propyl hyroxylase. A younger age at onset, malignancy, and a positive family history are clinical parameters of high specificity, but low sensitivity for diagnosis. Genetic analysis for mutations in SDH genes for the patient and family members, and surveillance for the affected patient and family members, are necessary where there are no clear clinical or family indicators for the syndrome. We present a case of a large abdominal malignant PGL in a 20-year-old pt. that went on without clinical detection for at least three years.
Aim(s): To present a young individual with a large abdomino-pelvic malignant paraganglioma with disseminated metastases that was functionally largely quiescent for catcoholamine excess, and that had harbored SDHB mutation. The aim is to underscore phenotypic heterogeneity of the disease and the attendant therapeutic challenges.
Materials and methods: A 20-year-old single male was referred with a 3-year history of a large skull occipital mass and a large abdominal incidentaloma. He had a core biopsy of the abdominal mass done at an external hospital, with a diagnosis of paraganglioma. Under our observation, the patient had frequent round-the-clock blood pressure monitoring for eight weeks. Imaging studies consisted of CT scans of the abdomen, chest and pelvis, CT of the head and neck, 1-123 MIBG scan, Octreoscan, whole body bone scan, skeletal survey, and abdominal angiogram in preparation for repeated tumor embolization preoperatively to decrease tumor vascularity. Hormonal and biochemical studies were done afterward: 24-h urinary metanephrine and normetanephrine determinations x3, urinary epinephrine, norepinephribe, dopamine, serum-free catecholamies, and dopamine, chromogranin A (CGA), calcitonin, CEA antigen, CBC, liver and kidney function tests. Molecular genetic studies for mutations in SHDB, SHDC and SDHD, VHL, RET were also carried out.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohammed Ahmed

To read results and conclusion, please login ...

Further abstracts you may be interested in

#106 Gastroenteropancreatic neuroendocrine tumors: single institution clinicopathological study
Introduction: Neuroendocrine cells are widely distributed throughout the body, and neoplasms from these dispersed cells can arise at many sites. They are distinguished into two broad categories: 1) Tumors identified as small cell lung carcinomas with biology and natural history of a high-grade malignancy and characteristics of small cell undifferentiated or anaplastic appearance by light microscopy. The WHO categorizes these tumors as poorly-differentiated neuroendocrine carcinomas; 2) Well-defined neuroendocrine tumors (NETs) with variable, but most lyindolent biologic behavior and characteristic well-differentiated histologic features. The majority arise in the gastrointestinal tract and collectively they are referred as gastroenteropancreatic neuroendocrine tumors (GEP/NETs). They include carcinoid tumors, pancreatic islet cell tumors (gastrinoma, insulinoma, glucagonoma, VIPoma, somatostatinoma), paragangliomas, pheochromocytomas, and medullary thyroid carcinomas. The WHO classifies the GEP/NETs as well-differentiated NETs (carcinoid tumors) if they are noninvasive and have benign behavior or uncertain malignant potential. In contrast, GEP/NETs with characteristics of low-grade malignancy with invasion of the muscularis propria or beyond, or metastases, are characterized as well-differentiated neuroendocrine carcinomas (malignant carcinoids). Pancreatic islet cell tumors, whether functioning or not, are classified as well-differentiated NETs or well-differentiated neuroendocrine carcinomas, due to the (depending on) histologic characteristics. The WHO classification for gastroenteropancreatic NETs based on stage (ie size and presence of metastases) and grade (mitotic rate, perineural and lymphovascular invasion, Ki-67 proliferative index) categorizes them as well-differentiated NETs, e.g., carcinoid tumors, or as well-differentiated neuroendocrine carcinomas.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Michael M. Vaslamatzis
#124 Management and outcomes of malignant paragangliomas and phaeochromocytomas
Introduction: Chromaffin-cell tumors include phaeochromocytomas and paragangliomas, represent a rare group of neuroendocrine tumors and are located in adrenal medulla or extra-adrenal sites, respectively. Ten percent of phaeochromocytomas and 15-35% of paragangliomas are malignant.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: DR Christos Toumpanakis
#145 Paragangliomas: a series of five cases
Introduction: Paraganglioma is a rare extraadrenal neuroendocrine tumor, composed of chromaffin cells and arising from the neural crest. The head, neck, and retroperitoneum are the most common sites for paraganglioma.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Assoc. Professor Catalina Poiana
Authors: Poiana C, Carsote M, Paun D, Hortopan D, ...
#273 The Succinate Dehydrogenase Genetic Testing in Patients with Extra-adrenal Paragangliomas: The Portuguese Cancer Center (Lisboa) Experience
Introduction: Extra-adrenal paragangliomas (PGLs) occur as sporadic or familial entities, the latter mostly in association with germline mutations of the SDHB, SDHC or SDHD genes.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Rita Domingues
#287 Lutetium-177 DOTATATE Therapy in the Management of Neuroendocrine Tumors
Introduction: Peptide receptor radionuclide therapy (PRRT) is a specific targeted treatment for NETs expressing somatostatin receptors. 177Lu-DOTATATE is one of several newly available compounds for this treatment.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Richard W Carroll